With the U.S. Supreme Court likely to decide on the constitutionality of the Affordable Care Act, it is instructive to understand the relevant policy positions of the largest physician organization in the country.
When identifying underrepresented subgroups deserving of special recruitment efforts for research participation, social determinants of health other than race should be given more consideration.
Extending immunosuppressive drug coverage for the lifetime of kidney patients, instead of only covering dialysis, would be a cost-effective way for the federal government to reduce the costs of posttransplant care while improving clinical outcomes for patients.
It is difficult to argue that consumers are maximizing their welfare by consuming trans fats, particularly because the production and taste costs of replacing them do not outweigh the health benefits.